Headlines about Cerus (NASDAQ:CERS) have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerus earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.8577831685435 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Cerus Co. (CERS) SVP Sells $13,246.15 in Stock (americanbankingnews.com)
- Cerus Co. (CERS) CEO Sells $37,128.00 in Stock (americanbankingnews.com)
- Eye-Catching Shares – Cerus Corporation (NASDAQ: CERS) – Alpha Beta Stock (alphabetastock.com)
- Cerus Announces the Fourth Biologics License Application (BLA) Approval for a US Blood Center Customer – Business Wire (press release) (businesswire.com)
- Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer (finance.yahoo.com)
Shares of Cerus (CERS) opened at $5.13 on Wednesday. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $5.43. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.89 and a quick ratio of 3.26. The firm has a market capitalization of $638.25, a PE ratio of -9.16 and a beta of 2.16.
Several research firms have recently weighed in on CERS. BTIG Research reissued a “hold” rating on shares of Cerus in a report on Thursday, January 25th. Zacks Investment Research downgraded Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. BidaskClub raised Cerus from a “hold” rating to a “buy” rating in a report on Tuesday, March 6th. Cantor Fitzgerald reissued a “buy” rating and issued a $5.00 target price on shares of Cerus in a report on Tuesday, January 23rd. Finally, Robert W. Baird reissued a “buy” rating and issued a $5.00 target price on shares of Cerus in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $5.00.
In other Cerus news, CEO William Mariner Greenman sold 7,735 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $4.80, for a total transaction of $37,128.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 14,381 shares of company stock valued at $69,685. 7.40% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Cerus (CERS) Earning Somewhat Positive Press Coverage, Report Shows” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3260626/cerus-cers-earning-somewhat-positive-press-coverage-report-shows.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.